These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 20940279)

  • 1. PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer.
    Dupont Jensen J; Laenkholm AV; Knoop A; Ewertz M; Bandaru R; Liu W; Hackl W; Barrett JC; Gardner H
    Clin Cancer Res; 2011 Feb; 17(4):667-77. PubMed ID: 20940279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer.
    Chandarlapaty S; Sakr RA; Giri D; Patil S; Heguy A; Morrow M; Modi S; Norton L; Rosen N; Hudis C; King TA
    Clin Cancer Res; 2012 Dec; 18(24):6784-91. PubMed ID: 23092874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancer.
    Arthur LM; Turnbull AK; Renshaw L; Keys J; Thomas JS; Wilson TR; Lackner MR; Sims AH; Dixon JM
    Breast Cancer Res Treat; 2014 Aug; 147(1):211-9. PubMed ID: 25104442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer.
    Gonzalez-Angulo AM; Ferrer-Lozano J; Stemke-Hale K; Sahin A; Liu S; Barrera JA; Burgues O; Lluch AM; Chen H; Hortobagyi GN; Mills GB; Meric-Bernstam F
    Mol Cancer Ther; 2011 Jun; 10(6):1093-101. PubMed ID: 21490305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.
    Razis E; Bobos M; Kotoula V; Eleftheraki AG; Kalofonos HP; Pavlakis K; Papakostas P; Aravantinos G; Rigakos G; Efstratiou I; Petraki K; Bafaloukos D; Kostopoulos I; Pectasides D; Kalogeras KT; Skarlos D; Fountzilas G
    Breast Cancer Res Treat; 2011 Jul; 128(2):447-56. PubMed ID: 21594665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
    Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H
    PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PIK3CA mutational status in circulating tumor cells can change during disease recurrence or progression in patients with breast cancer.
    Markou A; Farkona S; Schiza C; Efstathiou T; Kounelis S; Malamos N; Georgoulias V; Lianidou E
    Clin Cancer Res; 2014 Nov; 20(22):5823-34. PubMed ID: 25398847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer.
    Pérez-Tenorio G; Alkhori L; Olsson B; Waltersson MA; Nordenskjöld B; Rutqvist LE; Skoog L; Stål O
    Clin Cancer Res; 2007 Jun; 13(12):3577-84. PubMed ID: 17575221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
    Toomey S; Eustace AJ; Fay J; Sheehan KM; Carr A; Milewska M; Madden SF; Teiserskiene A; Kay EW; O'Donovan N; Gallagher W; Grogan L; Breathnach O; Walshe J; Kelly C; Moulton B; Kennedy MJ; Gullo G; Hill AD; Power C; Duke D; Hambly N; Crown J; Hennessy BT
    Breast Cancer Res; 2017 Jul; 19(1):87. PubMed ID: 28750640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression.
    Kalinsky K; Heguy A; Bhanot UK; Patil S; Moynahan ME
    Breast Cancer Res Treat; 2011 Sep; 129(2):635-43. PubMed ID: 21617917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer.
    McCarthy AM; Kumar NP; He W; Regan S; Welch M; Moy B; Iafrate AJ; Chan AT; Bardia A; Armstrong K
    BMC Cancer; 2020 Apr; 20(1):347. PubMed ID: 32326897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.
    Loibl S; von Minckwitz G; Schneeweiss A; Paepke S; Lehmann A; Rezai M; Zahm DM; Sinn P; Khandan F; Eidtmann H; Dohnal K; Heinrichs C; Huober J; Pfitzner B; Fasching PA; Andre F; Lindner JL; Sotiriou C; Dykgers A; Guo S; Gade S; Nekljudova V; Loi S; Untch M; Denkert C
    J Clin Oncol; 2014 Oct; 32(29):3212-20. PubMed ID: 25199759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted biomarker profiling of matched primary and metastatic estrogen receptor positive breast cancers.
    Schleifman EB; Desai R; Spoerke JM; Xiao Y; Wong C; Abbas I; O'Brien C; Patel R; Sumiyoshi T; Fu L; Tam RN; Koeppen H; Wilson TR; Raja R; Hampton GM; Lackner MR
    PLoS One; 2014; 9(2):e88401. PubMed ID: 24520381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The predictive role of phosphatase and tensin homolog (PTEN) loss, phosphoinositol-3 (PI3) kinase (PIK3CA) mutation, and PI3K pathway activation in sensitivity to trastuzumab in HER2-positive breast cancer: a meta-analysis.
    Wang Y; Liu Y; Du Y; Yin W; Lu J
    Curr Med Res Opin; 2013 Jun; 29(6):633-42. PubMed ID: 23574264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opposite Prognostic Impact of Single PTEN-loss and
    Lazaridis G; Kotoula V; Vrettou E; Kostopoulos I; Manousou K; Papadopoulou K; Giannoulatou E; Bobos M; Sotiropoulou M; Pentheroudakis G; Efstratiou I; Papoudou-Bai A; Psyrri A; Christodoulou C; Gogas H; Koutras A; Timotheadou E; Pectasides D; Zagouri F; Fountzilas G
    Cancer Genomics Proteomics; 2019; 16(3):195-206. PubMed ID: 31018950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PIK3CA Mutational Status Is Associated with High Glycolytic Activity in ER+/HER2- Early Invasive Breast Cancer: a Molecular Imaging Study Using [
    Magometschnigg H; Pinker K; Helbich T; Brandstetter A; Rudas M; Nakuz T; Baltzer P; Wadsak W; Hacker M; Weber M; Dubsky P; Filipits M
    Mol Imaging Biol; 2019 Oct; 21(5):991-1002. PubMed ID: 30652258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood.
    Higgins MJ; Jelovac D; Barnathan E; Blair B; Slater S; Powers P; Zorzi J; Jeter SC; Oliver GR; Fetting J; Emens L; Riley C; Stearns V; Diehl F; Angenendt P; Huang P; Cope L; Argani P; Murphy KM; Bachman KE; Greshock J; Wolff AC; Park BH
    Clin Cancer Res; 2012 Jun; 18(12):3462-9. PubMed ID: 22421194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study.
    Sabine VS; Crozier C; Brookes CL; Drake C; Piper T; van de Velde CJ; Hasenburg A; Kieback DG; Markopoulos C; Dirix L; Seynaeve C; Rea DW; Bartlett JM
    J Clin Oncol; 2014 Sep; 32(27):2951-8. PubMed ID: 25071141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PIK3CA mutations are a predictor of docetaxel plus epirubicin neoadjuvant chemotherapy clinical efficacy in breast cancer.
    Zhang Y; Liu M; Yang H; Wang J; Liu H; Li X; Li J; Xu J; Li X
    Neoplasma; 2014; 61(4):461-7. PubMed ID: 25027743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers.
    Castaneda CA; Lopez-Ilasaca M; Pinto JA; Chirinos-Arias M; Doimi F; Neciosup SP; Rojas KI; Vidaurre T; Balko JM; Arteaga CL; Gomez HL
    Hematol Oncol Stem Cell Ther; 2014 Dec; 7(4):142-8. PubMed ID: 25467032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.